Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1CNS 1

Conditions

Pheochromocytoma 3Paraganglioma 3Meningioma 3Prostatic Neoplasms 2Neuroendocrine Tumors 2Gastro-enteropancreatic neuroendocrine tumor 2Carcinoma, Neuroendocrine 2von Hippel-Lindau Disease 1Thyroid cancer, Hurthle cell 1Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Pancreatic Neoplasms 1Neuroectodermal Tumors, Primitive 1Neuroblastoma 1Neoplasms 1Multiple Endocrine Neoplasia Type 1 1Metastatic Neuroendocrine Prostate Cancer 1Kidney Neoplasms 1Hypertension 1Head and Neck Neoplasms 1Ganglioneuroma 1Ganglioneuroblastoma 1Breast Neoplasms 1Adenocarcinoma, Follicular 1

Interventions

relacorilant 3Osilodrostat 2sacubitril and valsartan sodium hydrate drug combination 1lutetium Lu 177 dotatate 1gallium Ga 68 dotatate 1enzalutamide 1bicalutamide 1Urine Specimen Collection 1Surveys and Questionnaires 1Standard of Care 1Receptors, Androgen 1Nutrition Assessment 1Leuprolide 1Interviews as Topic 1Holistic Health 1Goserelin 1Flutamide 1Blood Specimen Collection 1Biopsy 1Amlodipine 1Adrenalectomy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hypertension × gallium Ga 68 dotatate × 1 year × Clear all
NCT03206060 2026-04-24

Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma

National Institutes of Health Clinical Center (CC)

Phase 2 Recruiting
130 enrolled
CNSEndocrineNET

Hypertension, Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡